Related content

Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades

By  

ACTA NEUROLOGICA SCANDINAVICA (ELECTRONIC), Vol. 132, Iss. S199, 2015-07 ,pp. : 29-36

John Wiley & Sons Inc

Access to resources Recommend Favorite

Endothelial function measures: not for clinical prime time?

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 6, 2015-06 ,pp. : 624-625

John Wiley & Sons Inc

Access to resources Recommend Favorite

The need for better evidence for the use of Botulinum toxin A (BoNT‐A) in the treatment of children with CP: Lessons from Norway

By  

DEVELOPMENTAL MEDICINE & CHILD NEUROLOGY, Vol. 58, Iss. S5, 2016-09 ,pp. : 27-27

John Wiley & Sons Inc

Access to resources Recommend Favorite

Repeat blood cultures in children with persistent fever and neutropenia: Diagnostic and clinical implications

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 8, 2015-08 ,pp. : 1421-1426

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comments on the review article ‘Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades’

By  

ACTA NEUROLOGICA SCANDINAVICA (ELECTRONIC), Vol. 132, Iss. 5, 2015-11 ,pp. : 364-367

John Wiley & Sons Inc

Access to resources Recommend Favorite